Drugs / suramin
suramin
also known as
BAY-205 · BAYER-205 · CI-1003 · Farma · FARMA-939 · Fourneau · FOURNEAU 309 · Metaret · +13 more
Small molecule targets FGF1 via inhibition
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03804749 | Dec 2018 → Dec 2019 | hand, foot and mouth disease | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT00066768 | Jul 2003 → Mar 2008 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00006476 | Oct 2000 → Oct 2007 | urinary bladder cancer | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT00003038 | Oct 1997 → Jan 2003 | adrenal cortex carcinoma, breast cancer, cancer of unknown primary site, colorectal cancer +1 | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00001381 | Mar 1994 → Dec 2000 | transitional cell carcinoma, urinary bladder neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00083109 | Mar 2004 → Dec 2005 | renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00054028 | Dec 2002 → Mar 2008 | female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 210 trials · 1 missed | ||||||
| Phase 2 | NCT04496596 | Nov 2020 → Apr 2023 | acute kidney injury | Rediscovery Life Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT06058962 | Jun 2019 → Jan 2021 | autism spectrum disorder | Paxmedica | Completed | Missed primary |
| Phase 2 | NCT01671332 | Jun 2012 → Jun 2015 | non-small cell lung carcinoma | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT01038752 | Aug 2010 → Nov 2012 | non-small cell lung carcinoma | Optimum Therapeutics, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00006929 | Sep 2000 → Nov 2007 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00004073 | Dec 1999 → May 2003 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00002921 | Mar 1997 → Jan 2004 | adrenal cortex carcinoma | SWOG Cancer Research Network | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00002639 | Jul 1995 → May 2004 | brain cancer | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00002652 | May 1995 → Feb 2004 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT00001266 | Oct 1990 → Aug 2003 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT00002881 | Oct 1996 → Apr 1998 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002723 | Jan 1996 → Aug 2002 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02508259 Comparator | May 2015 → Mar 2016 | autism spectrum disorder | University of California, San Diego | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-07 | Paxmedica | Results PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal paxmedica.com ↗
Notably, the study revealed statistically significant improvements in the Clinical Global Impressions—Improvement (CGI-I) scale among the 10 mg/kg arm compared to the placebo group. |
All press releases naming this drug 5 releases
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | suramin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002652 ↗ |
| Known as | BAY-205 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | BAYER-205 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | CI-1003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Farma | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | FARMA-939 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Fourneau | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | FOURNEAU 309 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Metaret | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Nagananinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Naganol | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Naphuride | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | NF-060 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | NSC-34936 | “Suramin, SUR, NSC-34936.” NCT00002639 ↗ |
| Known as | NSC-758165 | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | SUR | “Suramin, SUR, NSC-34936.” NCT00002639 ↗ |
| Known as | SURAMIN HEXASODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Suramin Sodium | “Drug: Suramin Sodium” NCT06058962 ↗ |
| Known as | Suramina de sodio | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Suramine | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Suramine sodique | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Known as | Suraminum natricum | ChEMBL registry synonym — accepted as the source's own label CHEMBL265502 ↗ |
| Action | Inhibit | “Acidic fibroblast growth factor inhibitor” CHEMBL265502 ↗1“suramin (a growth factor inhibitor)” NCT00001266 ↗ |
| Modality | Small molecule | — CHEMBL265502 ↗ |
| Route | Other | “intravesical suramin” NCT00001381 ↗ |
| Target | FGF1 | “Acidic fibroblast growth factor inhibitor” CHEMBL265502 ↗ |